Author

Lijuan Meng

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Comparative efficacy and safety of protocol-defined 2-year versus indefinite immunotherapy strategies for advanced non-small-cell lung cancer: A systematic review and network meta-analysis

The optimal duration of immune checkpoint inhibitor (ICI)-based therapy for advanced non-small-cell lung cancer (NSCLC) remains uncertain. To compare first-line ICI-based regimens with a protocol-defined maximum treatment duration of approximately 2 years versus indefinite treatment. Systematic review...

Jia-Mei Yu, Qing Ling, Yi Jiao et al. · Therapeutic Advances in Medi... · 0 citations

Open access Jul 2026

Targeting the MDM2/Caspase-3/GSDME axis: apatinib and cinobufagin synergistically induce pyroptosis to suppress gastric cancer progression.

Overexpression of mouse double minute 2 homolog (MDM2) partially reversed these effects both in vitro and in vivo, leading to reduced apoptosis, pyroptosis, and antitumor efficacy.

Lei Cao, Lijuan Meng, Yueyao Lu et al. · Neoplasma (Bratislava) · 0 citations